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(CPE) have rarely been reported in dogs, and never in 
animals in Finland. However, in April 2015, two merope-
nem-resistant Escherichia coli were identified from two 
dogs in one family. Both dogs suffered from chronic oti-
tis externa.  Methods:  Epidemiological and molecu-
lar investigations (pulsed-field gel electrophoresis 
(PFGE), multilocus sequence typing) were conducted 
to investigate the source of infection and transmission 
routes. Results:  In both dogs and one family member 
New Delhi metallo-beta-lactamase (NDM-5)-producing 
multidrug-resistant ST167  E. coli  was found. Whole 
genome sequencing confirmed that the isolates were 
identical or only had one or two allelic differences. 
Additionally, the dogs and humans of the family car-
ried an identical extended-spectrum beta-lactamase 
(ESBL) CTX-M-group 9  E. coli  ST69 strain, indicating 
interspecies transmission. While the original source 
remains unclear, human-to-canine transmission is 
possible. No carbapenems had been administered to 
the dogs, but exposure to numerous other antimicro-
bials likely sustained the bacteria and supported its 
propagation in the canine host.  Conclusion:  To our 
knowledge, canine clinical NDM-5  E. coli  in Europe, 
and confirmed CPE transmission between dogs and 
humans have not been previously reported. The 
screening of veterinary Enterobacteriaceae isolates for 
carbapenem resistance is highly recommended.
Introduction
The rapid global emergence of resistance to carbape-
nem and other extended-spectrum beta-lactams in Ent
erobacteriaceae, Acinetobacter and Pseudomonas spec
ies in the past decade is a major public health concern 
[1,2]. With such types of resistance, these species have 
the potential to cause severe infection, especially in 
hospitalised individuals [3]. Carbapenem resistance 
is mediated by different types of carbapenemases, 
of which  Klebsiella pneumoniae  carbapenemase 
(KPC-type) and New Delhi metallo-beta-lactamase 
(NDM-type) carbapenemase are the most common in 
bacteria from human clinical specimens [2]. In addi-
tion to resistance to nearly all beta-lactams, isolates 
carrying carbapenemases are often multi- to exten-
sively drug-resistant (MDR or XDR), leaving very few or 
no treatment options [4]. Carbapenemase-producing 
MDR bacteria were first described almost exclusively 
in humans, but since 2011 have also been detected 
in livestock, companion animals, wildlife, and differ-
ent environmental compartments [5,6], indicating their 
transfer to new hosts and reservoirs. Carbapenem use 
in humans has been implicated as a cause of emerging 
carbapenem resistance [7]. Due to the MDR/XDR char-
acter of carbapenemase-producing bacteria, carbape-
nem resistance may also be co-selected for by the use 
of other antimicrobial classes [8]. Carbapenems are not 
authorised for veterinary use in Finland (Government 
decree 1054/2014) [9].
In Finland, carbapenemase-producing bacteria have 
been found in humans, although cases are still rare, 
with 20–34 new cases annually in 2013–16. Over half 
of these were probably of foreign origin [10]. However, 
such bacteria have never been identified in animals in 
the country. In the spring of 2015, meropenem-resist-
ant  Escherichia coli  was diagnosed from two canine 
ear specimens in the Clinical Microbiology Laboratory 
(CML) of the Faculty of Veterinary Medicine, University 
of Helsinki. The exceptional findings initiated epidemi-
ological and molecular investigations together with the 
Finnish Food Safety Authority (Evira) and the National 
Institute of Health and Welfare (THL). Here, we present 
the investigations and their results.
 




In spring 2015, two dogs, belonging to the same family, 
were found to have meropenem-resistant MDR E. coli in 
clinical specimens from their ears. Written consent for 
an epidemiological investigation was obtained from 
the owners. The investigation covered a timeline of up 
to two years before the findings. The medical records of 
the dogs were obtained from the treating veterinarian. 
The owners were asked to fill in an electronic question-
naire that covered their medical history including hospi-
talisations, human and animal contacts, travel history 
and the living conditions of the dogs. The family mem-
bers were also instructed to contact their local health-
care centre to consider screening for carbapenem and 
Table 1
Primers for extended-spectrum beta-lactamase, AmpC and carbapenemase multiplex PCRs and for sequencing of CTX-M 
group
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a Conditions for ESBL-, AmpC multiplex PCRs and for CTX-M-gene PCRs are reported in the following order: initial denaturation, denaturation, 
annealing, extension (30 cycles), and final extension.
b The same primers were used for PCR and sequencing.
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extended-spectrum cephalosporin-resistant bacteria. 
The presence of carbapenemase and other extended-
spectrum beta-lactamase-producing bacteria in the 
canine patients was followed for a year by taking speci-
mens from the dogs’ ears (4 occasions) and rectum (3 
occasions). In addition, a retrospective search of the 
records of the CML and the Reference Laboratory of 
THL was performed for the presence of respective  E. 
coli sequence types (ST) with similar antibiograms to 
those in this study.
Microbiological investigation
Laboratory methods for canine specimens
Clinical ear specimens were cultured on 5% sheep 
blood agar (tryptic soy agar with Sheep Blood, Oxoid, 
United Kingdom (UK)), a chromogenic agar (UriSelect 4, 
Bio-Rad, France) and Dixon agar plates (Tammertutkan 
Maljat, Finland). Bacteria were identified using bio-
chemical methods [11], while disk diffusion susceptibil-
ity testing, including quality control and interpretation, 
was performed according to Clinical and Laboratory 
Standards Institute (CLSI) guidelines with  E. coli  ATCC 
25922 as a quality control [12,13]. If no veterinary-spe-
cific susceptibility breakpoints were available, human 
CLSI breakpoints were used [14]. The susceptibility 
testing panel for Enterobacteriaceae included amikacin, 
amoxicillin-clavulanic acid, ampicillin, cefpodoxime, 
chloramphenicol, doxycycline, enrofloxacin, gen-
tamicin, meropenem and trimethoprim-sulfamethoxa-
zole (Oxoid, UK). Follow-up screening specimens from 
the ears and rectum were cultured on a selective agar 
(Brilliance ESBL, Oxoid, UK) and a blood agar plate with 
a 10 µg meropenem disk and incubated at + 35 ± 1 °C for 
up to 48 hours. Enterobacteriaceae isolates growing on 
the selective plate or showing reduced susceptibility 
to cefpodoxime (≤ 22 mm) or meropenem (≤ 22 mm) 
were identified and preserved for further research. 
Preliminary screening of carbapenemase activity was 
carried out using the modified Hodge test [14]. The 
type of beta-lactamase produced was confirmed by 
using commercial disk sets (carbapenemases: KPC + 
MBL Confirm ID Kit, Rosco Diagnostica, Denmark; 
ESBL/AmpC-type beta-lactamases: AmpC and ESBL 
Detection Set, Mast Group Ltd, UK). Carbapenemase 
activity was confirmed with ultraviolet-spectrometric 
detection of imipenem hydrolysis [15].
Bacterial strains from humans
Three extended-spectrum beta-lactamase (ESBL)/
carbapenemase-producing  E. coli  isolates isolated 
from rectal swabs of two human family members were 
received from the Helsinki-Uusimaa Hospital District 
Laboratory, HUSLAB. The rectal swabs were obtained 
and the specimens were cultured according to guide-
lines that have since been published [16]. In addition, 
susceptibility results were available from a fourth 
human ESBL E. coli isolated from a follow-up screening 
specimen. Sequence typing of the isolates was con-
ducted as further described. A search from the National 
Infectious Diseases Register at THL was performed 
to identify human  E. coli  isolates with similar ST and 
carbapenemase profiles in Finland in 2014–15. These 
were included in the core genome multilocus sequence 
typing (cgMLST) comparison (see below).
Molecular methods
Pulsed-field gel electrophoresis
Pulsed-field gel electrophoresis (PFGE) was per-
formed as previously described [17]. Clonal similar-
ity was determined using the Dice coefficient and the 
unweighted pair-group method using arithmetic aver-
age clustering (UPGMA), with the optimisation and tol-
erance both set to 1% (GelCompar software version 6, 
Applied Maths, Belgium).
Multilocus sequence typing and detection of beta-
lactamase-encoding genes by PCR
DNA for multilocus sequence typing (MLST) and PCR 
was extracted by suspending one to three bacterial 
colonies in 200 µL of PCR-grade water. The suspension 
was boiled for 10 min and centrifuged at 13,000 rpm for 
5 min. The supernatant was used as a DNA template.
For MLST, amplification of  adk,  fumC,  gyrB,  icd,  mdh
,  purA  and  recA  genes was performed using primers 
by Lau et al. [18], which were attached to universal 
forward (UniF: 5’-GTTTTCCCAGTCACGACGTTGTA-3’) 
and reverse (UniR: 5’-TTGTGAGCGGATAACAATTTC-3’) 
sequences at the 5’ end of each primer. The universal 
F and R sequences were used as sequencing primers. 
The PCR reaction mixture (total volume 20 µL) con-
tained 10 µL of 2x Phusion Flash High Fidelity Master 
Mix (Thermo Scientific, United States (US)), 0.25 µM 
of each primer (Oligomer Oy, Finland) and 1 µL of DNA 
template for all reactions, except for  icd, for which a 
primer concentration of 0.5 µM was used. PCR condi-
tions for  adk,  fumC  and  gyrB  were as follows: initial 
denaturation at 98 °C (15 s); 30 cycles of denaturation 
at 98 °C (2 s), annealing at 63 °C (10 s), elongation at 
Table 2
Antimicrobial treatmentsa the dogs had received before 
the NDM-Escherichia coli finding, Finland, 2013–2015
Dog A Dog B






































NDM: New-Delhi metallo-beta-lactamase producing.
a In addition, the dogs had received local and systemic 
corticosteroids.
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72 °C (15 s), and final elongation at 72 °C (60 s). The PCR 
parameters for  icd,  mdh,  purA  and  recA  multiplication 
were the same, except for an annealing temperature of 
59 °C (10 s).
Multiplex PCRs in a Phire Green Hot Start II PCR Master 
Mix (MM, total volume 20 µL) (Thermo Scientific, US) 
were performed to screen ESBL (CTX-M, TEM and SHV) 
and AmpC (CIT, DHA, ACC and FOX) gene families. All 
primers used in these and in the sequencing of CTX-
M, as well as PCR conditions, are presented in  Table 
1  [19-22]. The reaction mixture for ESBL multiplex PCR 
and CTX-M sequencing contained 15.4 µL of MM, 0.6 µL 
of dimethyl sulfoxide (DMSO), 0.25 µM of each primer 
(Oligomer Oy, Finland) and 1 µL of template DNA. The 
AmpC multiplex PCR contained 13.8 µL of MM, 0.6 µL 
of DMSO and 0.25 µM of each primer, except for FOX 
primers, for which the concentration was 0.4 µM. 
Carbapenemase gene families (KPC, IMP, VIM, NDM, 
OXA, GES, and IMI) were detected with multiplex PCR 
(Table 1) [15]. The reaction mixture contained 0.08 U/
μL of AmpliTaq Gold polymerase (Applied Biosystems, 
US) in a 1x reaction buffer (AmpliTag Gold buffer 10x 
Mg free, Applied Biosystems, US), 2.0 mM of MgCl2, 
0.2 mM of nt and 0.3 pmol/μL of each primer. A mixture 
of DNA from bacterial strains (characterised by THL) 
carrying either the ESBL (multiplex ESBL PCR), AmpC 
(multiplex AmpC PCR) or carbapenemase (multiplex 
carbapenemase) genes mentioned above were used 
as positive controls in the respective reactions. PCR-
grade water was used as a non-template control in 
each assay.
For sequencing of MLST genes and CTX-M, the PCR 
products were purified with  ExoI and FastAP (Thermo 
Scientific, US). Sequencing was performed at Macrogen 
Inc. (the Netherlands) using an ABI 3730 XL automated 
sequencer. MLST sequences were analysed using CLC 
Main Workbench (version 6.9.1, Qiagen, Denmark) and 
the CLC MLST module (version 1.4.7, Qiagen, Denmark). 
CTX-M sequencing data were analysed using CLC Main 
Workbench (version 7.5.1) and compared with the 
National Center for Biotechnology Information (NCBI) 
library.
Whole genome sequencing
DNA was extracted using the MagAttract HMW DNA Kit 
(Qiagen, Germany). Whole genome sequencing (WGS) 
was performed for carbapenem-resistant isolates using 
an Illumina MiSeq sequencer (Illumina Inc., US) with the 
Illumina Nextera XT DNA Sample Preparation Kit, the 
Nextera XT Index Kit with 24 indices for library prepara-
tion and MiSeq Reagent Kit V2 (300 cycles) using 150-
bp paired-end sequencing. The reads were compiled 
Table 3
Timeline and results of ear and screening specimens from dogs A and B, Finland, December 2013–May 2016 (n = 18 
specimens)





March 2015 Ear NDM-Escherichia coli P-1009
April 2015 Ear NDM-E. coli, CoNS P-1036
June 2015 Ear No growth NA
September 2015
Ear Moraxella sp. NA
Rectal swab ESBL-E. colia P-1112
December 2015
Ear Staphylococcus pseudintermedius, Acinetobacter sp., yeast NA
Rectal swab ESBL-E. colia NA
May 2016
Ear Non-specific growth NA
Rectal swab Negative NA
B
December 2013 Ear S. pseudintermedius, Acinetobacter baumannii NA
April 2015 Ear NDM-E. coli; MDR-E. coli (MEM-S) P-1044, (P-1043)b, P-1039
June 2015 Ear No growth NA
September 2015
Ear Mucor circinelloides (fungus) NA
Rectal swab ESBL-E. coli P-1113
December 2015
Ear S. pseudintermedius, Corynebacterium sp. NA
Rectal swab Negative NA
May 2016
Ear Non-specific growth NA
Rectal swab Negative NA
CoNS: coagulase-negative staphylococci; MDR: Multidrug resistant; MEM-S: meropenem susceptible; NA: not applicable (no isolate stored); 
NDM: New-Delhi metallo-beta-lactamase producing,
a Identical resistance profiles.
b P-1043 was identical to P-1044 (antibiogram, pulsed-field gel electrophoresis, multilocus sequence typing), except it had a rough colony 
type.
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using Velvet assembler version 1.1.04 included in 
Ridom SeqSphere + software (Ridom SeqSphere + ver-
sion 2.4.0; Ridom GmbH, Germany). Beta-lactamase 
resistance genes were detected using ResFinder 2.1 on 
the Center for Genomic Epidemiology (CGE) server [23]. 
Plasmids were detected using PlasmidFinder 1.3 [24].
An ad hoc core-genome MLST (cgMLST) protocol for E. 
coli,  containing 2,634 target alleles, was used on 
SeqSphere + to compare the strains originating from the 
family (i.e. the dogs and owners) to strains previously 
isolated from human patients in Finland, with similar 
ST and carbapenemase profile, which were identi-
fied from the National Infectious Diseases Register at 
THL. The  ad hoc  cgMLST scheme was created using 
the cgMLST Target Definer of Ridom SeqSphere soft-
ware and genome sequences obtained from GenBank. 
The whole-genome sequence of Escherichia coli strain 
G150 (GenBank accession number: LQHK01000008) 
was used as a reference strain and three E. coli strains, 
TW14588 (GenBank accession number: NZ_CM000662), 
453 (GenBank accession number: NZ_MPGR01000001) 
and 8368 (GenBank accession number: NZ_CP017444), 
were used as query genomes.
Results
Case presentations
The patients were two male Finnish Hound dogs, 
Dog A (five years-old) and Dog B (two-years old), liv-
ing in the same family. Both dogs had a long history 
of recurrent  otitis externa, the underlying factor of 
which was unidentified, although allergy/atopy was 
suspected. Dog A had its first otitis externa episode in 
February 2013, when a local veterinarian diagnosed ear 
inflammation with yeast overgrowth in the dog’s right 
ear. Dog B began experiencing ear problems in October 
2013. Both dogs continued to experience intermittent 
symptoms of ear infection, despite both topical and 
systemic antimicrobial (Table 2) and non-antimicrobial 
therapy, including corticosteroids.
Otitis media was diagnosed in the left ear of Dog A in 
November 2014, while the same condition had been 
diagnosed in the left ear of Dog B in December 2013. In 
March 2015, a bacteriological specimen from the left ear 
of Dog A was sent to the CML. The specimen revealed 
a meropenem-resistant MDR  E. coli  (for resistance 
profile, see Figure 1), but carbapenemase production, 
according to the modified Hodge’s test, appeared to be 
negative. At that time, the E. coli isolate was preserved 
for further investigation due to the unusual resistance 
profile. The veterinarian was informed about the unu-
sual phenotype and was advised to handle the dog with 
contact isolation precautions. Specimens from the ears 
of both dogs were taken in late April 2015. The speci-
men from Dog A again revealed meropenem-resistant 
MDR  E. coli, along with non-specific growth. This  E. 
coli  isolate gave a positive result for carbapenemase 
production in the modified Hodge’s test. This isolate 
and the earlier meropenem-resistant  E. coli  from Dog 
A were both metallo-beta-lactamase positive in the 
double-disk diffusion test. Dog B’s specimen initially 
revealed only MDR  E. coli  that was meropenem sensi-
tive, but after the meropenem-resistant  E. coli  finding 
from Dog A, Dog B’s specimen was re-cultured onto 
a chromogenic agar (UriSelect, Bio-Rad, US) on 
which a meropenem disc was placed. This revealed a 
Figure 1
Pulsed-field gel electrophoresis cluster analysis of the ESBL- and NDM- Escherichia coli strains isolated from two dogs and 
their owners, Finland, March 2015–September 2016 (n = 10 isolates)
XbaI-PFGE pattern Origin Strain ID Date (mo/yr) Antibiograma MLST type Resistance genotype BioSample accession
Dog A P-1112 09/2015 SSRRSRRSSS ST69 CTX-M Group 9 NA
Dog B P-1113 09/2015 SSRRSRRSSS ST69 CTX-M Group 9 NA
Human A O-58 05/2015 SSRRSRRSSS ST69 CTX-M Group 9 NA
Human B O-60 05/2015 SSRRSRRSSS ST69 CTX-M Group 9 NA
Dog A P-1009 03/2015 RRRRSSRRRR ST167 NDM-5, CMY-42, TEM-1B SAMN08329266
Dog A P-1036 04/2015 RRRRSSRRRR ST167 NDM-5, CMY-42, TEM-1B SAMN08329265
Dog B P-1039b 04/2015 SRRRSSRRSR ST167 CMY-42 SAMN08329267
Dog B P-1043c 04/2015 RRRRSSRRRR ST167 NDM-5, CMY-42, TEM-1B SAMN08329268
Dog B P-1044c 04/2015 RRRRSSRRRR ST167 NDM-5, CMY-42, TEM-1B SAMN08329269
Human A O-59 05/2015 RRRRSSRRRR ST167 NDM-5, CMY-42 SAMN08329270
ESBL: extended-spectrum beta-lactamase; MLST: multilocus sequence typing; NA: not available; NDM: New-Delhi metallo-beta-lactamase 
producing.
a Antibiogram is represented in the following order: amikacin, amoxicillin-clavulanic acid, ampicillin, cefpodoxime, chloramphenicol, 
doxycycline, enrofloxacin, gentamicin, meropenem, and trimethoprim-sulfamethoxazole.
b P-1039 is meropenem susceptible MDR-E. coli.
c These two strains were otherwise identical, but P-1043 had a rough colony type.
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meropenem-resistant E. coli isolate with the same anti-
biogram as Dog A’s isolates. Systemic treatment with 
antimicrobials was stopped and reasonable control of 
the ear infection in both dogs was achieved by topical 
chloramphenicol treatment and anti-inflammatory ther-
apy. The specimen histories of the dogs with respec-
tive findings are presented in Table 3.
Epidemiological investigation
The dogs were domestic Finnish Hounds from the same 
family in rural Eastern Finland. The family consisted of 
only two adults, and the only animals were the dogs 
in question. Both family members were of Finnish eth-
nicity. The dogs lived together in a fenced yard with a 
dog house and were used for hunting hares. Their diet 
mainly comprised hare and elk offal, in addition to raw 
commercial dog food (domestic). They also received 
cooked cow spines (domestic) and, occasionally, 
leather bones (unknown origin). The dogs were taken to 
the woods for hunting or training approximately three 
times per week. The dogs had not travelled outside of 
Finland and had not been in contact with other animals 
while at home. However, while hunting, they had con-
tact with wild animals, mainly hares, but probably also 
with mice and voles. The human family members had 
visited Estonia, Sweden, Norway and Croatia within the 
previous 2 years. Their medical history included hospi-
talisations in Finland, but not abroad. Neither of the 
dog owners worked in the healthcare sector.
Bacteriological and molecular investigations
The two human family members were screened on a 
voluntary basis for the presence of carbapenemase/
ESBL-producing Gram-negative rods. One of them car-
ried NDM- as well as ESBL-producing E. coli, while the 
other family member only carried ESBL-producing  E. 
coli.  Altogether, seven canine and three human  E. 
coli  isolates were further typed. One isolate (P-1043) 
from Dog B was identical to isolate P-1044 from the 
same dog, apart from colony morphology (Figure 1). 
All meropenem-resistant isolates (n = 5) belonged to 
ST167, had an identical antibiogram and PFGE profile, 
showed metallo-beta-lactamase activity, and were 
positive for NDM, CIT and TEM by multiplex PCR, except 
for the human isolate O-59, which was TEM-negative. 
In addition, one canine isolate susceptible to merope-
nem and amikacin belonged to the same cluster. All 
ESBL E. coli isolates (n = 4) were part of the same PFGE 
cluster and MLST type (ST69), with a characteristic 
antibiogram. Sequencing confirmed the presence of a 
CTX-M group 9 gene in the isolates of the latter cluster 
(Figure 1). 
WGS was performed on five canine ST167 E. coli isolates 
and the human NDM-positive ST167 isolate. Sequences 
were submitted to the NCBI BioSample database 
(see  Figure 1  for accession numbers). All five merope-
nem-resistant isolates carried NDM-5. All six isolates 
had CMY-42 in their WGS profile (Figure 1).
Figure 2


















cgMLST: core genome multilocus sequence typing; NDM: New-Delhi metallo-beta-lactamase producing.
Minimum spanning tree based on comparing of 2,634 target genes and ignoring missing values in pairwise comparison. The dashed circle 
defines the strains of this study. Strains H1 to H4 are NDM-5 positive E. coli ST167 strains from humans isolated in 2014 and 2015. The 
numbers above the lines connecting the strains indicate allelic differences. P-1036 and P-1009 are from dog A; P-1044, P-1043, and P-1039 are 
from Dog B (P-1043 was isolated together with P-1044, was otherwise similar but had a rough colony type). O-59 is from human A. All these 
were NDM-5 positive except for P-1039.
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Ad hoc  cgMLST grouped the six isolates very tightly: 
one strain from Dog A and the owner’s strain were 
identical, as were two strains from Dog B. Other 
strains, including one without NDM-5, had only 1 to 2 
allelic differences (Figure 2). The search for previous 
isolates in Finland of the same type and antibiogram 
as the ones found in the family revealed four human E. 
coli  ST167 isolates, all NDM-5 positive, from 2014–15. 
In the cgMLST analysis these isolates were clearly 
different from the strains of this study, differing in at 
least 67 alleles. All the NDM-5-positive  E. coli  strains 
of this study had IncI1- and IncFII-type plasmids, while 
the strain without the NDM-5 gene had only  IncI1-type 
plasmids.
A retrospective search of the CML database yielded 
CTX-M-positive  E. coli  ST167 isolates in horses in 
Finland, but these were vastly different in PFGE 
compared with the NDM-5 E. coli of this study (data not 
shown). No other previous E. coli ST69 of animal origin 
was observed.
Follow-up specimens
Carbapenemase-producing  E. coli  was not detected in 
canine follow-up specimens, but rectal screenings of 
both dogs in September 2015 yielded CTX-M-positive E. 
coli  ST69 (Table 3). Only one follow-up specimen 
was taken from human A, who originally carried both 
NDM and CTX-M-positive E. coli  strains. The follow-up 
specimen again yielded ESBL  E. coli  with a similar 
antibiogram to the other ST69 isolates in this study. 
However, this isolate was not available for typing.
Discussion
The results from molecular analyses strongly indi-
cate the transmission of ST167 NDM-5 and ST69 
CTX-M group 9  E. coli  between two dogs and 
humans in the same family. The transfer of ESBL-
producing  Enterobacteriaceae  between humans and 
dogs has previously been described [25], but to our 
best knowledge, this is the first report on the transmis-
sion of carbapenemase-producing E. coli between dogs 
and humans.
We consider that the transmission of ST167 NDM-5 had 
most likely occurred from human to dog. There are 
several reasons for this. Firstly, CPE are more frequent 
in humans than in animals [6]. Secondly, according to 
resistance surveillance, carbapenem-resistant bacteria 
have never been observed in animals in Finland before 
this report. They have, however, been observed with 
a gradually increasing frequency in humans, most of 
whom probably acquired the bacteria abroad [26]. In 
2008–15, among 31 Finnish human NDM cases, 11 were 
NDM-5 E. coli. Seven of these had been imported from 
India, and one each from Croatia, Thailand and Egypt, 
while one was of unknown origin [26]. The human fam-
ily members of this study had a history of hospitalisa-
tion in Finland, but not abroad. They also had visited 
Croatia in May 2013, which might be one possible ori-
gin for the NDM-5 E. coli ST167. The Balkan region has 
been reported as a potential reservoir of NDM genes, 
particularly NDM-1 [27]. It is also unlikely that the dogs 
had acquired NDM E. coli from their feed, although it is 
known that exposure to raw meat increases the risk of 
ESBL carriage in dogs [28,29]. However, carbapenem-
resistant isolates have not been detected in food-pro-
ducing animals in Finland [30], and even the presence 
of ESBL/AmpC-type beta-lactamases (CTX-M-1 and 
CMY-2) is deemed to be at a low level in Finnish live-
stock (0.8%, 1% and 8.1% in cattle, pigs and broilers, 
respectively in 2013–14) [31]. No data exist on the prev-
alence of CPE among wild animals or in the environment 
in Finland, and these cannot therefore be ruled out as 
potential sources of infection for the dogs or the own-
ers. However, the general level of resistance in Finnish 
wild animals was studied in 1999, and was found to be 
much lower than in the human population [32].
The origin of the CTX-M-9  E. coli  ST69 isolate is 
unclear. So far, ST69 E. coli have not been observed in 
companion animals in Finland (data not shown), while 
CTX-M is a common ESBL family among canine ESBL 
isolates [33]. However, no data are yet available on the 
genetic variants of canine CTX-M in Finland.
Reports concerning carbapenem-resistant bacteria in 
companion animals are uncommon [34-42]. In 2013, a 
US study reported six unrelated NDM  E. coli  isolates 
collected in 2008–2009 from five canine and one feline 
patient, of which four were confirmed to be NDM-1 [39]. 
This is interesting, since the first report of NDM-1 car-
bapenemase in a K. pneumoniae and an E. coli  isolate 
from a Swedish human patient of Indian origin was 
observed in 2008 and published a year later [43]. 
The first NDM-5-positive  E. coli  of animal origin was 
reported in an Algerian dog in 2015 [42]. The sequence 
type of the NDM-5 E. coli was ST1284, which is a double 
locus variant of  E. coli  ST167. In addition, OXA-48 has 
been observed in  E. coli  in companion animals (dogs 
and cats) in Algeria (2014–15) [37], the US (2009–13) 
[35] and France (dogs) (2015) [40], and in E. coli and K. 
pneumoniae  at a veterinary clinic in Germany (dogs) 
(2012) [41]. Furthermore, OXA-23  Acinetobacter  has 
been reported in dogs in France (2012) [36], VIM-1-
producing  K. pneumoniaein a dog in Spain (2014–15) 
[38], and IMP-4  Salmonella  Typhimurium in cats at 
an animal shelter in Australia (year not specified) 
[34]. Carbapenem-producing bacteria have also been 
reported in horses and food-producing animals (NDM 
in poultry and pigs, OXA-23 in dairy cows), as well as 
in environmental specimens (2003–13) [6].
It seems that the presence of carbapenemase-produc-
ing bacteria in animals is not linked to carbapenem 
use, since carbapenem products are not authorised 
for veterinary use [6]. Some off-label use could exist 
in companion animals according to the cascade prin-
ciple (Articles 10 and 11 of Directive 2001/82/EC) in 
the European Union [44], but the extent of such use 
is unknown. In Finland, however, national legisla-
tion prohibits the use of carbapenems in veterinary 
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medicine (Government decree 1054/2014). Our investi-
gation did not reveal any carbapenem use in the dogs 
of this study, but the selection pressure caused by 
numerous other antimicrobials was probably enough 
to co-select carbapenem resistance after the acquisi-
tion of carbapenem-resistant MDR E. coli. For example, 
ESBL-producing Enterobacteriaceae may be co-selected 
for by fluoroquinolone therapy [45]. Both dogs had 
received local as well as systemic fluoroquinolone 
therapy, which may have contributed to the survival of 
the MDR NDM-5 E. coli.
The NDM-5  E. coli  isolates in our study belonged to 
ST167. A database search revealed that only four ST167 
NDM-5-positive  E. coli  strains had previously been 
isolated from humans in Finland. In three cases, the 
patients had had contact abroad, i.e. Thailand, India 
and Egypt. The results of cgMLST analyses revealed 
that previous NDM-5 ST167  E. coli  were not related to 
the cluster of this study. Previously, the dissemination 
of NDM-5 has been linked to IncX3 plasmids [46], while 
the  IncI1 and  IncFII plasmids that were present in the 
NDM-5 isolates of this study have been associated with 
NDM-1 isolates [47].  IncFII was also identified from all 
previously isolated NDM-5 ST167  E. coli  strains that 
were investigated, although these were not related to 
the strains from the cases presented here. It is possible 
that all NDM-5-positive dog-cluster  E. coli  strains 
carried the NDM-5 gene in  IncFII-type plasmids, and 
the one carbapenem-susceptible strain without NDM-5 
had lost this plasmid.
As carbapenemase-producing strains and carbap-
enem resistance genes spread around the world due 
to travel and the international trade of food and feed, 
it is likely that such bacteria will be detected in ani-
mals in increasing numbers [5], as has been the case 
with ESBL/AmpC  Enterobacteriaceae. Close contact 
with companion animals increases the likelihood 
of human-to-animal CPE transmission. Once it has 
entered the animal population, a CPE can be efficiently 
co-selected by other antimicrobial classes due to the 
MDR character of CPE. The widespread use of antimi-
crobials in companion animals could thus enable them 
to act as reservoirs for CPE isolates and other resist-
ant bacteria. In our cases, all systemic antimicrobials 
were discontinued and only topical therapy was used. 
This may have facilitated the reduction of NDM-5 and 
ESBL  E. coli  below the level of detection in follow-up 
specimens.
An enrichment method for screening would have been 
more sensitive, but was not used, as it is not recom-
mended by the national guidelines. Furthermore, 
the use of the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) epidemiological cut-
off value (ECOFF) for meropenem (< 25 mm) [48] instead 
of the CLSI meropenem screening breakpoint (≤ 22 
mm) might have increased the likelihood of detecting 
non-wild-type isolates. However, as a clinical labora-
tory, adjusting breakpoints for this specific case was 
not considered necessary. Moreover, the meropenem 
histogram from  E.coli  isolates of the CML revealed 
that the CLSI breakpoint is capable of satisfactorily 
differentiating non-wild-type isolates from the wild-
type population.
In conclusion, to our knowledge, these are the first 
canine clinical NDM-5  E. coli  findings in Europe 
and this is the first confirmed case of transmission 
between dogs and humans. While the original source 
remains unclear, it is likely that either one or both of 
the dogs had acquired the strain from a human source. 
Although carbapenems had not been administered 
to these dogs, frequent exposure to diverse systemic 
antimicrobials probably facilitated the propagation of 
the bacteria in the canine host. It is vital for veterinary 
laboratories to remain alert, and to screen  Enterobact
eriaceaeisolates for carbapenem and third-generation 
cephalosporin resistance. This could be done by using 
suitable screening disks in testing panels or by using, 
for example, commercial screening plates for prelimi-
nary screening. Isolates with reduced susceptibility to 
carbapenems should be sent to a reference laboratory 
for confirmation. Furthermore, the veterinary commu-
nity should continue to emphasise the importance of 
prudent antimicrobial use.
Acknowledgements 
The authors wish to thank the owner of the dogs and the 
treating veterinarian for their excellent cooperation. We also 
thank laboratory personnel at the University of Helsinki, 
the Institute of Health and Welfare, and the Food Safety 
Authority Evira for their invaluable assistance. The Alfred 
Kordelin Foundation, the Finnish Veterinary Foundation, 
the Foundation for Canine Health Research, and the Finnish 
Foundation of Veterinary Research, the Finnish Cultural 
Foundation are thanked for their financial support. Roy 





MR and TG performed identification and susceptibility test-
ing, including ESBL phenotype and modified Hodge testing 
of the bacterial isolates. MR performed the CML database 
search for previous isolates. MR supervised and TG per-
formed the epidemiological investigation, MÖ and JJ per-
formed carbapenemase gene PCR, imipenem hydrolysis 
testing, WGS analysis and THL database search for previous 
isolates, ME performed PFGE, MLST and PCR for ESBL, SN 
and KP performed double disk diffusion for metallo-beta-lac-
tamase testing. All authors participated in the drafting the 
manuscript, and reviewed and approved the final version of 
the manuscript.
References
1. Shaikh S, Fatima J, Shakil S, Rizvi SM, Kamal MA. Antibiotic 
resistance and extended spectrum beta-lactamases: Types, 
9www.eurosurveillance.org
epidemiology and treatment. Saudi J Biol Sci. 2015;22(1):90-
101.  https://doi.org/10.1016/j.sjbs.2014.08.002  PMID: 
25561890 
2. Meletis G. Carbapenem resistance: overview of the problem 
and future perspectives. Ther Adv Infect Dis. 2016;3(1):15-21.  
https://doi.org/10.1177/2049936115621709  PMID: 26862399 
3. Wang Q, Zhang Y, Yao X, Xian H, Liu Y, Li H, et al. Risk 
factors and clinical outcomes for carbapenem-resistant 
Enterobacteriaceae nosocomial infections. Eur J Clin Microbiol 
Infect Dis. 2016;35(10):1679-89.  https://doi.org/10.1007/
s10096-016-2710-0  PMID: 27401905 
4. Lee CR, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. Global 
Dissemination of Carbapenemase-Producing Klebsiella 
pneumoniae: Epidemiology, Genetic Context, Treatment 
Options, and Detection Methods. Front Microbiol. 2016;7:895.  
https://doi.org/10.3389/fmicb.2016.00895  PMID: 27379038 
5. Guerra B, Fischer J, Helmuth R. An emerging public health 
problem: acquired carbapenemase-producing microorganisms 
are present in food-producing animals, their environment, 
companion animals and wild birds. Vet Microbiol. 2014;171(3-
4):290-7.  https://doi.org/10.1016/j.vetmic.2014.02.001  PMID: 
24629777 
6. Woodford N, Wareham DW, Guerra B, Teale C. Carbapenemase-
producing Enterobacteriaceae and non-Enterobacteriaceae 
from animals and the environment: an emerging public 
health risk of our own making? J Antimicrob Chemother. 
2014;69(2):287-91.  https://doi.org/10.1093/jac/dkt392  PMID: 
24092657 
7. McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, 
Scheetz MH. Correlations of antibiotic use and carbapenem 
resistance in enterobacteriaceae. Antimicrob Agents 
Chemother. 2013;57(10):5131-3.  https://doi.org/10.1128/
AAC.00607-13  PMID: 23836188 
8. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas 
ME, Giske CG, et al. Multidrug-resistant, extensively drug-
resistant and pandrug-resistant bacteria: an international 
expert proposal for interim standard definitions for acquired 
resistance. Clin Microbiol Infect. 2012;18(3):268-81.  https://
doi.org/10.1111/j.1469-0691.2011.03570.x  PMID: 21793988 
9. Valtioneuvoston asetus eräiden lääkeaineiden käytön 
kieltämisestä eläimille. [Government Decree concerning the 
prohibition of the use of certain veterinary medicinal products 
for animals]. Finlex Data Bank. Finnish. Available from: https://
www.finlex.fi/fi/laki/alkup/2014/20141054
10. National Institute for Health and Welfare (THL). Tartuntataudit 
Suomessa 2016. [Infectious diseases in Finland 2016]. 
Helsinki, Finland: THL; 2017. Report No.: 10/2015. Finnish.
11. Garcia LS, Isenberg HD. Clinical microbiology procedures 
handbook. 3rd ed. Washington, DC: ASM Press; 2010.
12. Clinical and Laboratory Standards Institute (CLSI). Performance 
Standards for Antimicrobial Disk and Dilution Susceptibility 
Tests for Bacteria Isolated From Animals: Approved Standard 
VET01-A4. Wayne, PA: CSLI; 2013.
13. Clinical and Laboratory Standards Institute (CLSI). Performance 
Standards for Antimicrobial Disk and Dilution Susceptibility 
Tests for Bacteria Isolated From Animals: Second Informational 
Supplement VET01-S2. Wayne, PA: CLSI; 2013.
14. Clinical and Laboratory Standards Institute (CLSI). Performance 
Standards for Antimicrobial Susceptibility Testing; Twenty-
Fourth Informational Supplement M100-S24. Wayne, PA: CSLI; 
2014.
15. Österblad M, Kirveskari J, Hakanen AJ, Tissari P, Vaara M, 
Jalava J. Carbapenemase-producing Enterobacteriaceae in 
Finland: the first years (2008-11). J Antimicrob Chemother. 
2012;67(12):2860-4.  https://doi.org/10.1093/jac/dks299  
PMID: 22855858 
16. National Institute for Health and Welfare (THL). Ohje 
moniresistenttien mikrobien tartunnantorjunnasta. [Manual 
on infection prevention for multi-drug resistant microbes]. 
Helsinki, Finland: THL; 2017. Report No.: 22/2017. Finnish.
17. Center for Disease Control and Prevention (CDC). One-Day 
(24-28 h) Standardized Laboratory Protocol for Molecular 
Subtyping of Escherichia coli O157:H7, non-typhoidal 
Salmonella serotypes, and Shigella sonnei by Pulsed Field Gel 
Electrophoresis (PFGE). Wayne, PA: CDC, PulseNet; 2013.
18. Lau SH, Reddy S, Cheesbrough J, Bolton FJ, Willshaw G, 
Cheasty T, et al. Major uropathogenic Escherichia coli strain 
isolated in the northwest of England identified by multilocus 
sequence typing. J Clin Microbiol. 2008;46(3):1076-80.  
https://doi.org/10.1128/JCM.02065-07  PMID: 18199778 
19. Mulvey MR, Soule G, Boyd D, Demczuk W, Ahmed RMulti-
provincial Salmonella Typhimurium Case Control Study 
Group. Characterization of the first extended-spectrum beta-
lactamase-producing Salmonella isolate identified in Canada. 
J Clin Microbiol. 2003;41(1):460-2.  https://doi.org/10.1128/
JCM.41.1.460-462.2003  PMID: 12517894 
20. Nyberg SD, Osterblad M, Hakanen AJ, Huovinen P, Jalava 
JThe Finnish Study Group For Antimicrobial Resistance. 
Detection and molecular genetics of extended-spectrum 
beta-lactamases among cefuroxime-resistant Escherichia 
coli and Klebsiella spp. isolates from Finland, 2002-
2004. Scand J Infect Dis. 2007;39(5):417-24.  https://doi.
org/10.1080/00365540601105731  PMID: 17464864 
21. Haanperä M, Forssten SD, Huovinen P, Jalava J. Typing of SHV 
extended-spectrum beta-lactamases by pyrosequencing in 
Klebsiella pneumoniae strains with chromosomal SHV beta-
lactamase. Antimicrob Agents Chemother. 2008;52(7):2632-5.  
https://doi.org/10.1128/AAC.01259-07  PMID: 18458132 
22. Pérez-Pérez FJ, Hanson ND. Detection of plasmid-mediated 
AmpC beta-lactamase genes in clinical isolates by using 
multiplex PCR. J Clin Microbiol. 2002;40(6):2153-62.  https://
doi.org/10.1128/JCM.40.6.2153-2162.2002  PMID: 12037080 
23. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen 
S, Lund O, et al. Identification of acquired antimicrobial 
resistance genes. J Antimicrob Chemother. 2012;67(11):2640-4.  
https://doi.org/10.1093/jac/dks261  PMID: 22782487 
24. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, 
Lund O, Villa L, et al. In silico detection and typing of plasmids 
using PlasmidFinder and plasmid multilocus sequence typing. 
Antimicrob Agents Chemother. 2014;58(7):3895-903.  https://
doi.org/10.1128/AAC.02412-14  PMID: 24777092 
25. Ljungquist O, Ljungquist D, Myrenås M, Rydén C, Finn M, 
Bengtsson B. Evidence of household transfer of ESBL-/pAmpC-
producing Enterobacteriaceae between humans and dogs - a 
pilot study. Infect Ecol Epidemiol. 2016;6(1):31514.  https://doi.
org/10.3402/iee.v6.31514  PMID: 27330043 
26. National Institute for Health and Welfare (THL). Tartuntataudit 
Suomessa 2015. [Infectious diseases in Finland 2015]. Helsinki, 
Finland: THL; 2016. Report No.: 10/2015.Finnish.
27. Berrazeg M, Diene S, Medjahed L, Parola P, Drissi M, Raoult D, 
et al. New Delhi Metallo-beta-lactamase around the world: an 
eReview using Google Maps. Euro Surveill. 2014;19(20):20809.  
https://doi.org/10.2807/1560-7917.ES2014.19.20.20809  PMID: 
24871756 
28. Nilsson O. Hygiene quality and presence of ESBL-producing 
Escherichia coli in raw food diets for dogs. Infect Ecol 
Epidemiol. 2015;5(1):28758.  https://doi.org/10.3402/iee.
v5.28758  PMID: 26490763 
29. Baede VO, Wagenaar JA, Broens EM, Duim B, Dohmen W, Nijsse 
R, et al. Longitudinal study of extended-spectrum-β-lactamase- 
and AmpC-producing Enterobacteriaceae in household dogs. 
Antimicrob Agents Chemother. 2015;59(6):3117-24.  https://doi.
org/10.1128/AAC.04576-14  PMID: 25779568 
30. FINRES-Vet. FINRES-Vet 2013-2015 Finnish Veterinary 
Antimicrobial Resistance Monitoring and Consumption of 
Antimicrobial Agents. Finnish Food Safety Authority Evira; 
2017. 68 p. Available from: www.evira.fi
31. Päivärinta M, Pohjola L, Fredriksson-Ahomaa M, Heikinheimo 
A. Low Occurrence of Extended-Spectrum β-lactamase-
Producing Escherichia coli in Finnish Food-Producing Animals. 
Zoonoses Public Health. 2016;63(8):624-31.  https://doi.
org/10.1111/zph.12277  PMID: 27215423 
32. Österblad M, Norrdahl K, Korpimäki E, Huovinen P. 
Antibiotic resistance. How wild are wild mammals? Nature. 
2001;409(6816):37-8.  https://doi.org/10.1038/35051173  PMID: 
11343104 
33. Jalava JVN, Miettinen S, Pelkonen S, Rantala M. Prevalence 
of third-generation cephalosporinresistant Escherichia coli 
and their resistance mechanisms in dogs in Finland, P1107 
abstract. 22nd ECCMID Conference; 31 March – 3 April 2012; 
London, UK; 2012.
34. Abraham S, O’Dea M, Trott DJ, Abraham RJ, Hughes D, Pang S, 
et al. Isolation and plasmid characterization of carbapenemase 
(IMP-4) producing Salmonella enterica Typhimurium from cats. 
Sci Rep. 2016;6(1):35527.  https://doi.org/10.1038/srep35527  
PMID: 27767038 
35. Liu X, Thungrat K, Boothe DM. Occurrence of OXA-48 
Carbapenemase and Other β-Lactamase Genes in ESBL-
Producing Multidrug Resistant Escherichia coli from Dogs 
and Cats in the United States, 2009-2013. Front Microbiol. 
2016;7:1057. PMID: 27462301 
36. Hérivaux A, Pailhoriès H, Quinqueneau C, Lemarié C, Joly-
Guillou ML, Ruvoen N, et al. First report of carbapenemase-
producing Acinetobacter baumannii carriage in pets from the 
community in France. Int J Antimicrob Agents. 2016;48(2):220-
1.  https://doi.org/10.1016/j.ijantimicag.2016.03.012  PMID: 
27424597 
37. Yousfi M, Touati A, Mairi A, Brasme L, Gharout-Sait A, Guillard 
T, et al. Emergence of Carbapenemase-Producing Escherichia 
coli Isolated from Companion Animals in Algeria. Microb 
Drug Resist. 2016;22(4):342-6.  https://doi.org/10.1089/
mdr.2015.0196  PMID: 26741510 
10 www.eurosurveillance.org
38. González-Torralba A, Oteo J, Asenjo A, Bautista V, 
Fuentes E, Alós JI. Survey of Carbapenemase-Producing 
Enterobacteriaceae in Companion Dogs in Madrid, Spain. 
Antimicrob Agents Chemother. 2016;60(4):2499-501.  https://
doi.org/10.1128/AAC.02383-15  PMID: 26824947 
39. Shaheen BW, Nayak R, Boothe DM. Emergence of a New 
Delhi metallo-β-lactamase (NDM-1)-encoding gene in 
clinical Escherichia coli isolates recovered from companion 
animals in the United States. Antimicrob Agents Chemother. 
2013;57(6):2902-3.  https://doi.org/10.1128/AAC.02028-12  
PMID: 23587948 
40. Melo LC, Boisson MN, Saras E, Médaille C, Boulouis HJ, 
Madec JY, et al. OXA-48-producing ST372 Escherichia coli in a 
French dog. J Antimicrob Chemother. 2017;72(4):1256-8. PMID: 
28039279 
41. Stolle I, Prenger-Berninghoff E, Stamm I, Scheufen S, 
Hassdenteufel E, Guenther S, et al. Emergence of OXA-
48 carbapenemase-producing Escherichia coli and 
Klebsiella pneumoniae in dogs. J Antimicrob Chemother. 
2013;68(12):2802-8.  https://doi.org/10.1093/jac/dkt259  
PMID: 23833179 
42. Yousfi M, Mairi A, Bakour S, Touati A, Hassissen L, Hadjadj L, 
et al. First report of NDM-5-producing Escherichia coli ST1284 
isolated from dog in Bejaia, Algeria. New Microbes New Infect. 
2015;8:17-8.  https://doi.org/10.1016/j.nmni.2015.09.002  
PMID: 26566444 
43. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et 
al. Characterization of a new metallo-beta-lactamase gene, 
bla(NDM-1), and a novel erythromycin esterase gene carried 
on a unique genetic structure in Klebsiella pneumoniae 
sequence type 14 from India. Antimicrob Agents Chemother. 
2009;53(12):5046-54.  https://doi.org/10.1128/AAC.00774-09  
PMID: 19770275 
44. Directive 2001/82/EC of the European Parliament and of the 
Council of 6 November 2001 on the Community code relating to 
veterinary medicinal products. OJ L 311, 28.11.2001, p. 1–66. 
Available from: https://eur-lex.europa.eu/legal-content/EN/
TXT/?uri=celex%3A32001L0082
45. Kantele A, Mero S, Kirveskari J, Lääveri T. Fluoroquinolone 
antibiotic users select fluoroquinolone-resistant ESBL-
producing Enterobacteriaceae (ESBL-PE) - Data of a prospective 
traveller study. Travel Med Infect Dis. 2017;16:23-30.  https://
doi.org/10.1016/j.tmaid.2017.01.003  PMID: 28153711 
46. Yang P, Xie Y, Feng P, Zong Z. blaNDM-5 carried by an IncX3 
plasmid in Escherichia coli sequence type 167. Antimicrob 
Agents Chemother. 2014;58(12):7548-52.  https://doi.
org/10.1128/AAC.03911-14  PMID: 25246393 
47. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt 
F, Balakrishnan R, et al. Emergence of a new antibiotic 
resistance mechanism in India, Pakistan, and the UK: a 
molecular, biological, and epidemiological study. Lancet Infect 
Dis. 2010;10(9):597-602.  https://doi.org/10.1016/S1473-
3099(10)70143-2  PMID: 20705517 
48. European Committee on Antimicrobial Susceptibility 
Testing (EUCAST). Antimicrobial wild type distributions of 
microorganisms: The European Committee on Antimicrobial 
Susceptibility Testing; Växjö: EUCAST; 2017. Available from: 
https://mic.eucast.org/Eucast2/
License and copyright
This is an open-access article distributed under the terms of 
the Creative Commons Attribution (CC BY 4.0) Licence. You 
may share and adapt the material, but must give appropriate 
credit to the source, provide a link to the licence, and indi-
cate if changes were made.
This article is copyright of the authors, 2018.
